Performances
RD Popularity Index
RD Growth Index
| 1h | 24h | 7d | 30d | 60d | 90d |
|---|---|---|---|---|---|
| 0.94% | 2.00% | 2.35% | 30.55% | 22.48% | 42.84% |
Comparison
Tokenomics
Unlock Progress
Based on CoinGecko data, Current Unlock Rate for BIO: 64.61%
Unlock Event
| Date | Unlocked Token Amount | Unlocked M.Cap | M.Cap (%) | Allocation |
|---|---|---|---|---|
| Dec 3, 2026 | 30.8M BIO | $592.39K | 1.44% | 6 Allocation |
| Jan 3, 2027 | 30.8M BIO | $592.39K | 1.44% | 6 Allocation |
| Feb 3, 2027 | 30.8M BIO | $592.39K | 1.44% | 6 Allocation |
Top Holders
| Address | Token | Quantity | Percentage | Value |
|---|---|---|---|---|
| 0x0d2a...2ef4 |   BIO | 858,793,928.84 | 25.87% | $16.49M |
| Binance 28 (efcb) | BIO | 240,541,483.82 | 7.25% | $4.62M |
| Binance 8 (acec) | BIO | 160,000,000 | 4.82% | $3.07M |
Open Markets
| # | Exchange | Pair | Price | +2% depth | -2% depth | Volume (24h) | volume % |
|---|---|---|---|---|---|---|---|
| 1 | HHTXCEX | BIO/USDT | $0.04415 | $1,049 | $6,796 | $3,176,875 | 48.30% |
| 2 | PPhemexCEX | BIO/USDT | $0.04437 | $1,116 | $1,435 | $725,200 | 11.03% |
| 3 | OOKXCEX | BIO/USDT | $0.04408 | $64,037 | $97,039 | $622,618 | 9.47% |
| 4 | BBitgetCEX | BIO/USDT | $0.04411 | $42,508 | $47,619 | $343,581 | 5.22% |
| 5 | BBingXCEX | BIO/USDT | $0.04417 | $86,953 | $101,283 | $317,543 | 4.83% |
| 6 | BBithumbCEX | BIO/KRW | $0.04437 | $12,704 | $7,377 | $283,104 | 4.30% |
| 7 | BIO/USD | $0.04404 | $61,343 | $59,938 | $263,275 | 4.00% | |
| 8 | BIO/ETH | $0.0441 | $19,079 | $19,022 | $83,220 | 1.27% | |
| 9 | VITASTEM/BIO | $0.04401 | $1,588 | $1,583 | $13,002 | 0.20% | |
| 10 | BIO/CRYO | $0.04411 | $3,020 | $3,010 | $4,515 | 0.07% |
Follow Updates
Follow Lists
People
About BIO Protocol
BIO Protocol is a funding and governance protocol for decentralised science that splits research into BioDAOs, where token holders vote on what to fund and the resulting intellectual property is issued as tradable IP tokens whose proceeds return to the treasury. It supplies shared infrastructure for curation, fundraising and liquidity bootstrapping: each BioDAO raises independently and holds its IP share while the protocol layer coordinates cross-DAO liquidity and governance, so teams can launch without incorporating first, while funders join topic selection and milestone review, closing a loop from grants to IP monetisation and handing capital allocation to peers rather than a single fund.
On June 19, 2026 at DeSci.Berlin it launched OpenLabs, merging AI-assisted research, community voting and on-chain governance into one funding desk. The trade-off is that research cycles run far longer than token cycles, IP is hard to price, curation quality depends on voter participation, and the gap between liquidity and price makes it closer to venture-style betting.
Bio Protocol completed a $6.9 million seed round led by Arthur Hayes. It later listed on Upbit supporting KRW/BTC/USDT pairs. OpenLabs launched to back scientific projects and agent collaboration via USDC revenue. Bio V2 will introduce IP tokens sold through Ignition Sales; first BioAgent project Aubrai was oversubscribed 14.6x. The protocol generated over $4 million in liquidity fees and is preparing DeFi integrations.
Product and ecosystem: On June 19, 2026 at DeSci.Berlin, Bio Protocol launched OpenLabs, combining AI-assisted research, community voting and on-chain governance into a funding platform, with RheumaAI and PeptAI as the first projects; BIO Genesis has raised over $33 million. BIO nonetheless fell more than 8% in the 24 hours after the announcement.
Market and supply: Chainalysis data on October 5 showed about $2 billion of won-denominated BIO volume in the 12 months to June, fourth among AI tokens in Korea, and on October 6 GLP-1 aging data from Eli Lilly and Novo Nordisk sparked a DeSci rally. About 1.175 billion tokens (35%) remain locked, the protocol wallet has moved 80 million to exchanges, and roughly $4.71 million of TVL against a $114 million FDV leaves a clear valuation premium.
In September 2026 Bio Protocol launched Open Science Index, cataloguing 6,720 open-source resources across biology, chemistry, physics, materials and earth science; its Launchpad added credit-card funding through Privy, and a redesigned site gathered BIOS, OpenLabs, Buildspace, Launchpad and Biofy under one entry point. That month NeuroLab's Ignition Sale closed 2.2x oversubscribed with more than 442,000 USDC committed by over 650 participants.
OpenLabs launched in July to compress the gap between a funded proposal and lab work, and PeptAI was selected for Track 2 of the Adaptyv Bio and Anthropic protein design competition, receiving three months of Claude Max 20x and $500 in Modal compute. The platform has facilitated over $900,000 in research funding and minted more than 1,000 hypotheses on-chain.
Future strategy and roadmap: BIO Protocol is linking BioDAOs, tokenized intellectual property and BioAgents into a closed loop from hypothesis to wet-lab work to commercialization; OpenLabs already shortened the path from proposal to experiment. Next it will expand institutional research funding and corporate partnerships, route Biofy application revenue back into research, and lower participation barriers via Launchpad credit-card top-ups and Privy onboarding while growing the Open Science Index open-source resource count.
Paul Kohlhaas, Founder and CEO. Founder and CEO of Molecule and co-founder of VitaDAO, formerly at ConsenSys and a Swiss government blockchain project. Founded BIO Protocol in 2024, leading its protocol design, coordination layer and tokenomics.
Clemens Ortlepp, Co-Founder and CPO. Founder of MTX Studio, focused on decentralized technology innovation. Leads BIO Protocol's client product design, building friendly interaction and efficient workflows.
Jose Pinto, Legal Counsel. Responsible for BIO Protocol's compliant operations, token issuance review and IP protection, addressing cross-border crypto regulatory challenges.
James Sinka, Head of R&D and Community. Leads iteration of the underlying blockchain technical architecture and operates the global community of scientists, patients and enthusiasts.
William Fang, Head of Strategy. Responsible for BIO Protocol's strategy and ecosystem expansion, connecting crypto and biotech resources, advancing BioDAO.
BIO Protocol charges a 1% trading fee on secondary market trades, applicable to the initial BIO/Token liquidity pool automatically deployed by the platform, with the fee split automatically by the smart contract at 70% to the project treasury and 30% to Bio.xyz.